Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin

Oncogene volume 39, pages 219–233 (2020)Cite this article

Subjects

Abstract

Elevated CUB-domain containing protein 1 (CDCP1) is predictive of colorectal cancer (CRC) recurrence and poor patient survival. While CDCP1 expression identifies stem cell populations that mediate lung metastasis, mechanisms underlying the role of this cell surface receptor in CRC have not been defined. We sought to identify CDCP1 regulated processes in CRC using stem cell populations, enriched from primary cells and cell lines, in extensive in vitro and in vivo assays. These experiments, demonstrating that CDCP1 is functionally important in CRC tumor initiation, growth and metastasis, identified CDCP1 as a positive regulator of Wnt signaling. Detailed cell fractionation, immunoprecipitation, microscopy, and immunohistochemical analyses demonstrated that CDCP1 promotes translocation of the key regulators of Wnt signaling, β-catenin, and E-cadherin, to the nucleus. Of functional importance, disruption of CDCP1 reduces nuclear localized, chromatin-associated β-catenin and nuclear localized E-cadherin, increases sequestration of these proteins in cell membranes, disrupts regulation of CRC promoting genes, and reduces CRC tumor burden. Thus, disruption of CDCP1 perturbs pro-cancerous Wnt signaling including nuclear localization of β-catenin and E-cadherin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  CAS  PubMed  Google Scholar 

  2. Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36:1461–73.

    Article  CAS  PubMed  Google Scholar 

  3. Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.

    Article  CAS  PubMed  Google Scholar 

  4. Novellasdemunt L, Antas P, Li VS. Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: proteins, pathways and mechanisms. Am J Physiol Cell Physiol. 2015;309:C511–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.

    Article  CAS  Google Scholar 

  6. Mazzoni SM, Fearon ER. AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Lett. 2014;355:1–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Morgan RG, Ridsdale J, Tonks A, Darley RL. Factors affecting the nuclear localization of beta-catenin in normal and malignant tissue. J Cell Biochem. 2014;115:1351–61.

    Article  CAS  PubMed  Google Scholar 

  8. Krieghoff E, Behrens J, Mayr B. Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci. 2006;119:1453–63.

    Article  CAS  PubMed  Google Scholar 

  9. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. EMBO J. 2012;31:2714–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci. 1999;112:1237–45.

    Article  CAS  PubMed  Google Scholar 

  11. Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP. ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells. World J Gastroenterol. 2007;13:6581–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ganesh S, Shui X, Craig KP, Koser ML, Chopda GR, Cyr WA, et al. Beta-Catenin mRNA silencing and MEK inhibition display synergistic efficacy in preclinical tumor models. Mol Cancer Ther. 2018;17:544–53.

    Article  CAS  PubMed  Google Scholar 

  13. Bruun J, Kolberg M, Nesland JM, Svindland A, Nesbakken A, Lothe RA. Prognostic significance of beta-Catenin, E-Cadherin, and SOX9 in colorectal cancer: results from a large population-representative series. Front Oncol. 2014;4:118.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene. 2003;22:1783–94.

    Article  CAS  PubMed  Google Scholar 

  15. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, et al. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009;15:2311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ikeda J, Oda T, Inoue M, Uekita T, Sakai R, Okumura M, et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci. 2009;100:429–33.

    Article  CAS  PubMed  Google Scholar 

  17. Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Liu H, et al. Identification of CDCP1 as a hypoxia-inducible factor 2alpha (HIF-2alpha) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci USA. 2013;110:3483–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Adams MN, Harrington BS, He Y, Davies CM, Wallace SJ, Chetty NP, et al. EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. Oncogene. 2015;34:1375–83.

    Article  CAS  PubMed  Google Scholar 

  19. Harrington BS, He Y, Davies CM, Wallace SJ, Adams MN, Beaven EA, et al. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. Br J Cancer. 2016;114:417–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, et al. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene. 2016;35:468–78.

    Article  CAS  PubMed  Google Scholar 

  21. Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res. 2010;70:5136–46.

    Article  CAS  PubMed  Google Scholar 

  22. Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, et al. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. Cell Rep. 2015;11:564–76.

    Article  CAS  PubMed  Google Scholar 

  23. Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, et al. CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget. 2016;7:69649–65.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, et al. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014;74:5229–43.

    Article  CAS  PubMed  Google Scholar 

  25. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol. 2007;27:7649–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene. 2012;31:3924–38.

    Article  CAS  PubMed  Google Scholar 

  27. Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene. 2014;33:255–68.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Deryugina EI, Conn EM, Wortmann A, Partridge JJ, Kupriyanova TA, Ardi VC, et al. Functional role of cell surface CUB domain-containing protein 1 in tumor cell dissemination. Mol Cancer Res. 2009;7:1197–211.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wright HJ, Hou J, Xu B, Cortez M, Potma EO, Tromberg BJ, et al. CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proc Natl Acad Sci USA. 2017;114:E6556–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Benes CH, Wu N, Elia AE, Dharia T, Cantley LC, Soltoff SP. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell. 2005;121:271–80.

    Article  CAS  PubMed  Google Scholar 

  31. Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA, et al. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. J Biol Chem. 2012;287:9792–803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM, et al. Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. J Biol Chem. 2011;286:42303–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci USA. 2011;108:1931–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Chou CT, Li YJ, Chang CC, Yang CN, Li PS, Jeng YM, et al. Prognostic significance of CDCP1 expression in colorectal cancer and effect of its inhibition on invasion and migration. Ann Surg Oncol. 2015;22:4335–43.

    Article  PubMed  Google Scholar 

  35. Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene. 2001;20:4402–8.

    Article  CAS  PubMed  Google Scholar 

  36. Gao W, Chen L, Ma Z, Du Z, Zhao Z, Hu Z, et al. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. Gastroenterology. 2013;145:636–46e5.

    Article  CAS  PubMed  Google Scholar 

  37. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell. 2011;9:357–65.

    Article  CAS  PubMed  Google Scholar 

  38. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104:10158–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.

    Article  PubMed  CAS  Google Scholar 

  40. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.

    Article  CAS  PubMed  Google Scholar 

  41. Margolin DA, Myers T, Zhang X, Bertoni DM, Reuter BA, Obokhare I, et al. The critical roles of tumor-initiating cells and the lymph node stromal microenvironment in human colorectal cancer extranodal metastasis using a unique humanized orthotopic mouse model. FASEB J. 2015;29:3571–81.

    Article  CAS  PubMed  Google Scholar 

  42. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, et al. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell. 1996;86:391–9.

    Article  CAS  PubMed  Google Scholar 

  43. Brocardo M, Lei Y, Tighe A, Taylor SS, Mok MT, Henderson BR. Mitochondrial targeting of adenomatous polyposis coli protein is stimulated by truncating cancer mutations: regulation of Bcl-2 and implications for cell survival. J Biol Chem. 2008;283:5950–9.

    Article  CAS  PubMed  Google Scholar 

  44. Heuberger J, Birchmeier W. Interplay of cadherin-mediated cell adhesion and canonical Wnt signaling. Cold Spring Harb Perspect Biol. 2010;2:a002915.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Law ME, Corsino PE, Jahn SC, Davis BJ, Chen S, Patel B, et al. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene. 2013;32:1316–29.

    Article  CAS  PubMed  Google Scholar 

  46. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Brown TA, Yang TM, Zaitsevskaia T, Xia Y, Dunn CA, Sigle RO, et al. Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. J Biol Chem. 2004;279:14772–83.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was funded by grant 2010–09 from the Wesley Research Institute to JWL and JDH, grants APP1021827 and APP1045801 from the Cancer Council Queensland, grant APP1121970 from the National Health and Medical Research Council to JDH, and Future Fellowship FT120100917 from the Australian Research Council to JDH, and NHMRC Early Career Fellowship 1091589 to MNA.

Author information

Authors and Affiliations

  1. Mater Research Institute—University of Queensland, Woolloongabba, Qld, 4102, Australia

    Yaowu He, Claire M. Davies, Brittney S. Harrington, Yonghua Sheng, Thomas McGann, Kate Bastick, Laurie Zhong, Andy Wu, Kuan Yau Wong, Mark N. Adams, James S. Palmer, Lez J. Burke, Adam D. Ewing, Rohan Lourie, Bhuvana Srinivasan, Michael A. McGuckin & John D. Hooper

  2. Mater Health Services, South Brisbane, Qld, 4101, Australia

    Claire M. Davies, Amy Broomfield, Rohan Lourie, Admire Matsika & Bhuvana Srinivasan

  3. Ochsner Clinic Foundation, New Orleans, LA, USA

    Linh Hellmers, Grace Maresh, Shannon McChesney, Ryan C. Sullivan, Xin Zhang, David Margolin & Li Li

  4. School of Biomedical Sciences, University of Queensland, St Lucia, Qld, 4072, Australia

    Admire Matsika

  5. Wesley Hospital, Auchenflower, Qld, 4066, Australia

    John W. Lumley

Authors
  1. Yaowu He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claire M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brittney S. Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linh Hellmers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yonghua Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amy Broomfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas McGann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kate Bastick
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Laurie Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Andy Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Grace Maresh
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shannon McChesney
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kuan Yau Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mark N. Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ryan C. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. James S. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Lez J. Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Adam D. Ewing
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. David Margolin
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Rohan Lourie
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Admire Matsika
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Bhuvana Srinivasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Michael A. McGuckin
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. John W. Lumley
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. John D. Hooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design were performed by YH and JDH. Acquisition of data was performed by YH, CMD, BSH, LH, YS, AB, TM, KB, LZ, AW, GM, SM, KYW, MNA, RCS, JSP, LJB, ADE, RL, AM, and BS. Administrative, technical and material support were provided by XZ, MM, DM and JWL. Data analysis and interpretation were performed by YH, LL, and JDH. Drafting of the manuscript was performed by YH, LL, and JDH, and all authors reviewed the manuscript.

Corresponding author

Correspondence to John D. Hooper.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, Y., Davies, C.M., Harrington, B.S. et al. CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin. Oncogene 39, 219–233 (2020). https://doi.org/10.1038/s41388-019-0983-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41388-019-0983-3

This article is cited by

Search

Advanced search

Quick links